InvestorsHub Logo
Followers 8
Posts 472
Boards Moderated 0
Alias Born 10/21/2009

Re: None

Friday, 01/17/2014 1:22:35 PM

Friday, January 17, 2014 1:22:35 PM

Post# of 130502
Anyone care to elaborate on this statement from todays blog entry. TIA
Moreover, the fact that Eltoprazine fits strategically with our MANF Parkinson’s program and has received substantial non-dilutive funding to generate the highly statistically significant data produced in the most recent PD LID trial suggests that we are now well positioned from an asset standpoint and we will be seeking clinical data and upcoming milestones to support valuation